| association id |
FEATURE |
Drug id |
Propr |
Public |
Drug Name |
Drug Target |
N FEATURE pos |
N FEATURE neg |
log max Conc tested |
FEATURE neg logIC50 MEAN |
FEATURE pos logIC50 MEAN |
FEATURE deltaMEAN IC50 |
FEATURE IC50 effectSize |
FEATURE neg Glass delta |
FEATURE pos Glass delta |
ANOVA FEATURE pval |
Tissue ANOVA pval |
MSI ANOVA pval |
ANOVA FEATURE FDR % |
a25 |
ASXL1_mut |
1013 |
1 |
1 |
Nilotinib |
ABL |
16 |
784 |
0.693 |
2.71 |
-0.27 |
-2.98 |
2.3 ** |
2.4 ** |
0.92 . |
1.14e-09 |
2.27e-38 |
2.03e-01 |
0.00075 |
a211 |
ASXL1_mut |
1021 |
1 |
1 |
Axitinib |
PDGFR, KIT, VEGFR |
16 |
828 |
0.693 |
2 |
0.11 |
-1.89 |
1.5 * |
1.5 * |
0.94 . |
9.45e-05 |
2.99e-21 |
9.72e-01 |
7.4 |
a405 |
ASXL1_mut |
1014 |
1 |
1 |
RDEA119 |
MAP2K1 (MEK1), MAP2K2 (MEK2) |
15 |
822 |
1.61 |
1.56 |
-0.188 |
-1.75 |
0.97 . |
0.97 . |
0.99 . |
4.83e-04 |
7.56e-51 |
1.05e-01 |
20 |
a408 |
ASXL1_mut |
1019 |
1 |
1 |
Bosutinib |
SRC, ABL, TEC |
16 |
832 |
0.693 |
1.78 |
-0.0662 |
-1.85 |
1.3 * |
1.3 * |
2 ** |
4.9e-04 |
1.35e-27 |
1.12e-01 |
20 |
